Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

From the authors

P. M. A. Calverley, P. Albert
European Respiratory Journal 2008 32: 1131; DOI: 10.1183/09031936.00102108
P. M. A. Calverley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Albert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

We thank L. Mascitelli and colleagues for their interesting comments about the role of the renin–angiotensin system in severe chronic obstructive pulmonary disease. Our review 1 was intended to provide guidance on current established therapies rather than consider potential future treatment options and hence we did not include a comment relevant to this interesting but, as yet, unproven treatment approach. The only data we are aware of that directly addresses this were published recently in the European Respiratory Journal and did not find improvements in pre-specified outcomes after blockade of the renin–angiotensin system 2. This does not preclude a role for this system in some settings in chronic obstructive pulmonary disease; however, it did make us cautious about commenting specifically on the role of these drugs in a review of current disease management.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Albert P, Calverley PMA. Drugs (including oxygen) in severe COPD. Eur Respir J 2008;31:1114–1124.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Andreas S, Herrmann-Lingen C, Raupach T, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006;27:972–979.
      OpenUrlAbstract/FREE Full Text
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 32 Issue 4 Table of Contents
    European Respiratory Journal: 32 (4)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    From the authors
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    From the authors
    P. M. A. Calverley, P. Albert
    European Respiratory Journal Oct 2008, 32 (4) 1131; DOI: 10.1183/09031936.00102108

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    From the authors
    P. M. A. Calverley, P. Albert
    European Respiratory Journal Oct 2008, 32 (4) 1131; DOI: 10.1183/09031936.00102108
    Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Reply: Central apnoeas, sympathetic activation and mortality in heart failure
    • Central apnoeas, sympathetic activation and mortality in heart failure
    • Reply: Triple therapy and adverse cardiovascular events in COPD
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society